Systemic exposure to atorvastatin between asian and caucasian subjects: A combined analysis of 22 studies

American Journal of Therapeutics

Volumn 19, Issue 3, 2012, Pages 164-173

  Gandelman, Kuan ^a   Fung, Gordon L ^b   Messig, Michael ^a   Laskey, Rachel ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ATORVASTATIN; GEMFIBROZIL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BODY WEIGHT; CAUCASIAN; CHINA; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; FEMALE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL; SINGAPORE; SINGLE DRUG DOSE; UNITED KINGDOM;

ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRROLES; YOUNG ADULT;

EID: 84861189463     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181f28fb5     Document Type: Article

References (32)

1. Committee on Safety of Medicines and MRHA. Statins and cytochrome P450 interactions. Curr Prob Pharmacovigil. 2004;30:1-2.
2. Davidson MH, Robinson JG. Safety of aggressive lipid management. J Am Coll Cardiol. 2007;49:1753-1762. (Pubitemid 46617861)
3. Lee E, Ryan S, Birmingham B, et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther. 2005;78:330-341 (Pubitemid 41393668)
4. European medicines agency. Crestor, summary of product characteristics. Astra Zeneca. Available at: http://www.emea. europa.eu/pdfs/human/referral/ Crestor/Crestor%20-%20 Annexes%20I,%20II,%20III%20-EN.pdf. Accessed April 28, 2010.
5. Birmingham BK, Azumaya CT, Wei C, et al. Increased exposure levels of Rosuvastatin, Atorvastatin and Simvastatin in Chinese and Japanese subjects: a class effect? Clin Pharmacol Ther. 2008;83:S15.
6. Pfizer Ltd. Lipitor® (atorvastatin calcium) full prescribing information. Available at: http://www.pfizer.com/ files/products/uspilipitor. pdf. Accessed April 28, 2010.
7. Oishi S. Atorvastatin (CI-981) Clinical pharmacokinetic study (I) Relative bioavailability of amorphous and crystalline preparations of atorvastatin. Jpn Pharmacol Ther. 1998;26:67-78. (Pubitemid 28455302)
8. Chung M, Calcagni A, Glue P, et al. Effect of food on the bioavailability of amlodipine besylate/atorvastatin calcium combination tablet. J Clin Pharmacol. 2006;46:1212-1216. (Pubitemid 44387422)
9. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokin. 2003;42:1141-1160. (Pubitemid 37357650)
10. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther. 2002;301:1042-1051. (Pubitemid 34595097)
11. Chen C, Mireles RJ, Campbell SD, et al. Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos. 2005;33:537-546. (Pubitemid 40393197)
12. Kameyama Y, Yamashita K, Kobayashi K, et al. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogen Genom. 2005;15:513-522. (Pubitemid 41017600)
13. Wu X, Whitfield LR, Stewart BH. Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm Res. 2000;17:209-215. (Pubitemid 30158371)
14. Mizutani T. PM frequencies of major CYPs in Asians and Caucasians. Drug Metab Rev. 2003;35:99-106. (Pubitemid 37048293)
15. Tirona RG. Ethnic differences in statin disposition. Clin Pharmacol Ther. 2005;78:3112316.
16. Peters BJ, Klungel OH, de Boer A, et al. Genetic determinants of response to statins. Expert Rev Cardiovas Ther. 2009;7:9772983.
17. Neuvonen PJ. Drug interactions with HMG-CoA re-ductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetic. Curr Opin Invest Drugs. 2010;11:3232332.
18. Niemi M. Transporter pharmacogenetics and statin toxicity. Clin Pharmacol Ther. 2010;87:1302133.
19. Keskitalo JE, Zolk O, Fromm MF, et al. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther. 2009; 86:1972203.
20. Gradhand U, Kim RB. Pharmacogenomics of MRP transporters (ABCC1-5) and BCRP (ABCG2). Drug Metab Rev. 2008;40:3172354.
21. Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol. 2009;5:7032729.
22. Zhang W, Yu BN, He YJ, et al. Role of BCRP 421C.A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta. 2006;373: 992103.
23. Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol. 2007;99:4102414.
24. Holford NH. A size standard for pharmacokinetics. Clin Pharmacokin. 1996;30:3292332.
25. Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokin. 1997;33:3132327.
26. CADUET (amlodipine besylate/atorvastatin calcium) tablets [US Prescribing Information]. Pfizer Inc.
27. Guidance for Industry. Bioequivalence recommendations for specific products (Draft Guidance May 2007). US Food and Drug Administration, 2007.
28. Guidance on atorvastatin calcium. US Food and Drug Administration. Available at: http://www.fda.gov/ downloads/Drugs/ GuidanceComplianceRegulatoryInf-ormation/Guidances/ucm082580.pdf. Accessed April 28, 2010.
29. Bao W, DaSilva E, Sun C-C, et al. Safety of atorvastatin in Asian patients within clinical trials [abstract P2-4]. Int J Cardiol. 2007;122:S82.
30. Crestor® (rosuvastatin calcium) [full prescribing information]. Astra Zeneca. Available at: http://www.astra zeneca-us.com/pi/crestor.pdf. Accessed April 28, 2010.
31. Saito M, Hirata-Koizumi M, Urano T, et al. A literature search on pharmacokinetic drug interactions of statins and analysis of how such interactions are reflected in package inserts in Japan. J Clin Pharm Ther. 2005;30: 21237.
32. Malinowski HJ, Westelinck A, Sato J, et al. Same drug, different dosing: differences in dosing for drugs approved in the United States, Europe, and Japan. J Clin Pharmacol. 2008;48:9002908.